), an innovator and pioneer in developing products for the treatment of sleep-disordered breathing and respiratory conditions. The Food and Drug Administration (FDA) recently cleared ResMed's home ...
Background The increasing number of patients treated by long-term non-invasive ventilation (NIV) challenges the capacity of ...
STIMIT AG announced today it is enrolling patients in its FDA Investigational Device Exemption (IDE) clinical trial, “STIMIT ACTIVATOR 1 PIVOTAL STUDY,” with world renowned clinical centers. STIMIT’s ...
In hospitalized veterans with COVID-19, obstructive sleep apnea (OSA) was associated with greater use of non-invasive ventilation (NIV), but booster vaccination reduced this risk, a retrospective ...
Newly released Medicare national coverage determinations are set to reshape the home ventilation landscape for chronic obstructive pulmonary disease (COPD). The final determination of coverage ...
Industry stakeholders and patient advocacy groups are raising concerns with CMS due to high denial rates for non-invasive ventilators (NIVs) by Medicare Advantage plans. Industry stakeholders and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback